큐라티스
Financials
Valuation Metrics
큐라티스's Market Cap is ₩580B. At end of 2025 it was ₩1457B. Ranked #1674 of 2,421 in KR market (top 69%), #1006 of 1,640 on KOSDAQ (top 61%), #180 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.98B KRW | KR#1,674/2,421 Sec#180/231 |
| Revenue | 1.10B KRW | KR#2,385/2,421 Sec#217/231 |
| Net Income | -23.90B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 58.09B KRW | KR#2,125/2,421 Sec#187/231 |
| Net Assets | 47.28B KRW | KR#1,945/2,421 Sec#162/231 |
| Employees | 72 | KR#1,861/2,421 Sec#160/231 |
| Value | ||
| P/B | 1.23x | KR#1,640/2,421 Sec#109/231 |
| P/S | 52.90x | KR#2,375/2,421 Sec#198/231 |
| FCF Yield | -26.35% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -50.54% | KR#2,278/2,421 Sec#197/231 |
| ROA | -41.13% | KR#2,349/2,421 Sec#211/231 |
| Op. Margin | -892.81% | KR#2,380/2,421 Sec#213/231 |
| Revenue Growth | -41.14% | KR#2,265/2,421 Sec#201/231 |
| Financial Health | ||
| Debt Ratio | 22.87% | KR#433/2,421 Sec#52/231 |
| Total Debt | 9.43B KRW | KR#1,645/2,421 Sec#148/231 |
| FCF | -15.28B KRW | KR#1,828/2,421 Sec#168/231 |
| Cash | 11.97B KRW | KR#1,588/2,421 Sec#134/231 |
| Current Ratio | 1.29x | KR#1,406/2,421 Sec#146/231 |
| Performance | ||
| 1Y Return | -50.69% | KR#2,064/2,421 Sec#190/231 |
| 1M Return | 68.03% | KR#32/2,421 Sec#5/231 |
| From 52W High | -65.16% | KR#2,038/2,421 Sec#165/231 |
| 1Y MDD | -84.62% | KR#2,357/2,421 Sec#225/231 |
| Trading | ||
| Volume | 2,472,442 shares | KR#56/2,421 Sec#5/231 |
| Trading Value | 12.45B KRW | KR#223/2,421 Sec#16/231 |
| Foreign Own. | 0.83% | KR#2,092/2,421 Sec#204/231 |
| Per Share | ||
| EPS | -1,863 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,686 KRW | KR#1,730/2,421 Sec#127/231 |
Company Info
Established in 2016, this company possesses vaccine development platform technology and was listed on KOSDAQ in 2023. It is developing preventive vaccines for adult and adolescent tuberculosis, schistosomiasis, and next-generation mRNA COVID-19, operating manufacturing facilities and research laboratories that meet cGMP, EU-GMP, and KGMP standards. Utilizing its vaccine development platform technology, the company conducts the entire new drug development process and offers services and consulting to bio new drug development clients. Curatis, established in 2016, is headquartered in Chungcheongbuk Province, Cheongju City.